The research focuses on people with pre-diabetes, a condition where blood sugar levels are higher than normal but not high enough to be called diabetes. Participants will receive the oral medication Metformin in a film‑coated tablet form, while a comparable group will receive a placebo. The single aim of the trial is to determine whether Metformin can modify biological signs of inflammation and the aging process that are linked to the activation of the NLRP3 inflammasome, a protein complex that helps trigger inflammatory responses.

During the study, volunteers will attend regular visits over an 18‑month period, beginning with a baseline assessment and followed by follow‑up visits roughly every six months. At each visit, blood samples will be taken to measure levels of several substances that indicate inflammation, such as IL-1β, IL-6, and TNFα, as well as markers of blood vessel health, clotting, oxidative stress, and cellular aging. Simple explanations of these markers will be provided, for example, describing them as signals that the body uses to show whether inflammation or stress is occurring. Additional tests will track changes in weight, blood sugar control, and cholesterol levels. The overall design allows researchers to compare the changes in these measurements between the Metformin group and the placebo group to see if the drug influences the biological processes associated with aging and inflammation.